Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response


Muckenhuber A., Berger A. K. , Schlitter A. M. , Steiger K., Konukiewitz B., Trumpp A., ...More

CLINICAL CANCER RESEARCH, vol.24, no.2, pp.351-359, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 2
  • Publication Date: 2018
  • Doi Number: 10.1158/1078-0432.ccr-17-2180
  • Title of Journal : CLINICAL CANCER RESEARCH
  • Page Numbers: pp.351-359

Abstract

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with a dismal prognosis and poor therapeutic response to current chemotherapy regimens in unselected patient populations. Recently, it has been shown that PDAC may be stratified into functionally and therapeutically relevant molecular subgroups and that some of these subtypes can be recapitulated by IHC for KRT81 [quasi-mesenchymal (QM)/squamous/basal-like] and HNF1A (non-QM, overlap with exocrine/ADEX subtype).